Cisplatin plus gemcitabine chemotherapy in taxane/anthracycline-resistant metastatic breast cancer. (Record no. 18820908)

MARC details
000 -LEADER
fixed length control field 01558 a2200469 4500
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20250515170023.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 200907s 0 0 eng d
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 1421-9794
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.1159/000214143
Source of number or code doi
040 ## - CATALOGING SOURCE
Original cataloging agency NLM
Language of cataloging eng
Transcribing agency NLM
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Somali, Isil
264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Date of production, publication, distribution, manufacture, or copyright notice 20090728
245 00 - TITLE STATEMENT
Title Cisplatin plus gemcitabine chemotherapy in taxane/anthracycline-resistant metastatic breast cancer.
Medium [electronic resource]
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Name of publisher, distributor, etc. Chemotherapy
Date of publication, distribution, etc. 2009
300 ## - PHYSICAL DESCRIPTION
Extent 155-60 p.
Other physical details digital
500 ## - GENERAL NOTE
General note Publication Type: Journal Article
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Adult
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Aged
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Anthracyclines
General subdivision therapeutic use
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Antineoplastic Combined Chemotherapy Protocols
General subdivision therapeutic use
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Breast Neoplasms
General subdivision drug therapy
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Bridged-Ring Compounds
General subdivision therapeutic use
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Cisplatin
General subdivision administration & dosage
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Deoxycytidine
General subdivision administration & dosage
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Drug Resistance, Neoplasm
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Drug Therapy, Combination
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Female
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Humans
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Middle Aged
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Neoplasm Metastasis
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Survival Rate
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Taxoids
General subdivision therapeutic use
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Gemcitabine
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Alacacioglu, Ahmet
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Tarhan, Mustafa Oktay
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Meydan, Nezih
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Erten, Cigdem
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Usalp, Songul
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Yilmaz, Ugur
773 0# - HOST ITEM ENTRY
Title Chemotherapy
Related parts vol. 55
-- no. 3
-- p. 155-60
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://doi.org/10.1159/000214143">https://doi.org/10.1159/000214143</a>
Public note Available from publisher's website

No items available.